Diospyros villosa Root Monographic Quality Studies.

Diospyros villosa L. (De Winter) (Ebenaceae) is a shrub whose root (DVR) is used as a toothbrush and to treat oral infections in Mozambique. The present work aims at establishing monographic quality criteria to allow the sustainable and safe development of pharmaceutical preparations with this herbal drug. This includes setting botanical (qualitative and quantitative) and chemical identification parameters, purity tests (loss on drying and total ash), quantifying the major classes of constituents identified, and particle size characterization of the powdered drug. DVR samples are cylindrical and microscopically characterized by: a periderm, with six layers of flattened phellem cells, with slightly thickened walls and few layers of phelloderm; cortical parenchyma with brachysclereids with a short, roughly isodiametric form (13.82-442.14 µm2 × 103), surrounded by a ring of prismatic calcium oxalate crystals; uniseriate medullary rays and prominent vessels of the xylem with single or double shape; numerous single and clustered starch grains, within the cortical parenchyma, medullar parenchyma, and ray cells. Polyphenols, mainly hydrolyzable tannins (212.29 ± 0.005 mg gallic acid equivalent/g of dried DVR), are the main marker class of constituents. Furthermore, the average diameter of the particles of the powder, 0.255 mm, allows its classification as a fine powder.

Anacardium occidentale Bark as an Antidiabetic Agent.

Anacardium occidentale L. is used throughout the world to treat type 2 diabetes. In Portugal, a traditional herbal preparation made with stem bark of this species (AoBTHP) has been used for more than 30 years to treat this pathology. The AoBTHP was standardized on total phenolic content, and its hypoglycemic activity was assessed using db/db mice (n = 26) for 92 days. Three doses (40.2, 71.5, and 127.0 mg/kg/day, per os) were tested, and glibenclamide (5 mg/kg/day) was used as positive control. During the study, glycemia was measured under non-fasting or fasting states. In sequence, thin-layer chromatography bioautographic assays were used for the detection of possible alpha- and beta-glucosidase inhibitors. A significant hypoglycemic effect in fasting glycemia in days 31 and 57 was observed with the three tested doses. The 71.5 mg/kg and 127.0 mg/kg AoBTHPs significantly reduced non-fasting glycemia on day 24. The highest dose showed the most significant hypoglycemic effect. Gallic acid was identified as the major alpha- and beta-glucosidase inhibitor. The 127 mg/kg/day AoBTHP dose showed a greater glucose-lowering effect than glibenclamide. For the first time, a standardized AoBTHP was tested using an in vivo diabetes model, and its usage was preclinically validated for type 2 diabetes treatment. The hypoglycemic activity of an AoBTHP can be related to the presence of alpha- and beta-glucosidase inhibitors, such as gallic acid, but other mechanisms can also be involved.